Research Progress in Precision Targeted Drug Therapy for HER2-Positive Breast Cancer Patients

Xianguang Bai(Pingdingshan University)
Kai Yang(Pingdingshan University)
Shengle Tian(Pingdingshan University)
Longfei Zhao(Pingdingshan University)
Xuhang Ba(Pingdingshan University)
Yupeng Xia(Pingdingshan University)

Abstract

HER2-positive breast cancer is an aggressive subtype of breast cancer with poor prognosis. With the continuous development of targeted therapies, the treatment strategies and prognosis for this disease have significantly improved in recent years. This review summarizes the latest advances in the adjuvant and neoadjuvant therapies for early HER2-positive breast cancer, rescue therapies for advanced HER2-positive breast cancer, as well as treatments and prevention strategies for brain metastases in HER2-positive breast cancer. Additionally, the future direction of anti-HER2 targeted therapy is discussed, aiming to provide a reference for clinical treatment.

References

Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.

Xu A, Dong X, Li H, et al. Cancer statistics in China and the United States, 2022: Profiles, trends, and determinants. Chin Med J. 2022;135(5):584-590.

Johnson KS, Conant EF, Soo MS. Molecular subtypes of breast cancer: A review for breast radiologists. J Breast Imaging. 2021;3(1):12-24.

Perez EA, Romond EH, Suman V, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: Planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;32(33):3744-3752.

Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-1684.

Cameron D, Piccart-Gebhart M, Gelber RD, et al. Eleven years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: Final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389(10075):1195-1205.

Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273-1283.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34.

Azizi E, Carr AJ, Plitas G, et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell. 2018;174(5):1293-1308.

Lee KH, Kime Y, Yu JS, et al. The prognostic and predictive value of tumor-infiltrating lymphocytes and hematologic parameters in patients with breast cancer. BMC Cancer. 2018;18(1):938.

Loibl S, Jassem J, Sonnenblick A, et al. VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up. Ann Oncol. 2022;33(Suppl 7):S63-64.

Ruan M, Tian T, Rao J, et al. Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers. Diagn Pathol. 2018;13(1):66.

Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(12):1688-1700.

Li H, Liu J, Chen J, et al. A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Nat Commun. 2018;9(1):1614.

Broglio KR, Quintana M, Foster M, et al. Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis. JAMA Oncol. 2016;2(6):751-760.

Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): A multicenter, open-label, phase 2 randomized trial. Lancet Oncol. 2016;17(6):791-800.

Van der Voort A, van Ramshorst MS, van Werkhoven ED, et al. Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial. JAMA Oncol. 2021;7(7):978-984.

Hurvitz SA, Martin M, Symmans WE, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): A randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018;19(1):115-126.

Hurvitz SA, Martin M, Jung KH, et al. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. Clin Oncol. 2019;37(25):2206-2216.

Robidoux A, Tang G, Rastogi P, et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): An open-label, randomised phase 3 trial. Lancet Oncol. 2013;14(12):1183-1192.

Jacobs SA, Robidoux A, Abraham J, et al. NSABP FB-7: A phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer. Breast Cancer Res. 2019;21(1):133.

Wu Y, Jiang Z, Liu Z, et al. Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): A double-blind, randomized phase 3 trial. BMC Med. 2022;20(1):498.

Gelmon KA, Boyle FM, Kaufman B, et al. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. Clin Oncol. 2015;33(14):1574-1583.

Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(4):519-530.

Blackwell KL, Burstein H, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2 positive metastatic breast cancer: Final results from the ECF104900 Study. Clin Oncol. 2012;30(21):2585-2592.

Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. Clin Oncol. 2010;28(7):1138-1144.

Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): A descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(6):732-742.

Yan M, Bian L, Hu X, et al. Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): A randomized, double-blind, placebo-controlled phase 3 study. Transl Breast Cancer Res. 2020;1-13.

Man XR. Clinical efficacy of T-DM1 as third-line therapy for metastatic breast cancer. Clin Drug Ther. 2023;16(22):15-17+23.

Saura C, Oliveira M, Feng YH, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with > 2 HER2-directed regimens: Phase III NALA trial. Clin Oncol. 2020;38(27):3138-3149.

Rugo HS, Im SA, Cardoso F, et al. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021;7(4):573-584.

Luo SP, Zhang J, Yu YS, et al. Advances in targeted therapy for HER2-positive breast cancer. Chin J Clin Pharmacol Ther. 2023;28(08):876-886.

Soni A, Ren Z, Hameed O, et al. Breast cancer subtypes predispose the site of distant metastases. Am J Clin Pathol. 2015;143(4):471-478.

Yan M, Ouyang Q, Sun T, et al. Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): A multicenter, single-arm, two-cohort, phase 2 trial. Lancet Oncol. 2022;23(3):353-361.

Murthy R, Borges VF, Conlin A, et al. Tucatinib with trastuzumab in advanced HER2-positive capecitabine metastatic breast cancer with and without brain metastases: A nonrandomised, open-label, phase Ib study. Lancet Oncol. 2018;19(7):880-888.

Wang CC, Xiang JY, Zhang QY, et al. Intracranial efficacy of pyrotinib and capecitabine combination therapy in HER2-positive breast cancer with brain metastases. Drug Des Devel Ther. 2024;18:909-917.

Chan A, Moy B, Mansi J, et al. Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial. Clin Breast Cancer. 2021;21(1):80-91.

Zhao Y, Niu XY, Han ZF, et al. Progress and prospects of antibody-drug conjugates in HER2-positive breast cancer. Modern Oncol Med. 2025;33(05):876-882.

Ahn HK, Sim SH, Suh KJ, et al. Response rate and safety of a neoadjuvant pertuzumab, atezolizumab, docetaxel, and trastuzumab regimen for patients with ERBB2-positive stage II/III breast cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2022;8(9):1271-1277.

DOI: http://dx.doi.org/10.26549/jor.v7i1.27960